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Resveratrol inhibits vascular smooth muscle cell
proliferation and induces apoptosis
Bertrand Poussier, MD,a Alfredo C. Cordova, MD,a Jean-Pierre Becquemin, MD,b
and Bauer E. Sumpio, MD, PhD,a New Haven, Conn; and Créteil, France
Objective: In France, despite a high intake of dietary cholesterol and saturated fat, the cardiovascular death rate is one of
the lowest among developed countries. This “French paradox” has been postulated to be related to the high red wine
intake in France. The aim of this study was to determine the effects of resveratrol, a major polyphenol component of red
wine, on vascular smooth muscle cell (SMC) proliferation in vitro.
Methods: SMCs were exposed to 106 to 104 M resveratrol and cell proliferation was assessed by cell counting. Cell cycle
analysis was done by treating cells with propidium iodide followed by flow-activated cell sorting. Apoptosis was
determined by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling staining.
Results: We demonstrate that resveratrol inhibited bovine aortic SMC proliferation in a dose-dependent manner. The
lowest concentration of resveratrol resulting in a significant decrease in SMC proliferation compared with control was
105 M. By flow cytometry, we observed a block in the G1-S phase of the SMC cycle. Resveratrol treatment also resulted
in a dose-dependent apoptosis of SMCs but had no effects on SMC morphology.
Conclusion: The results indicated that vascular SMC proliferation could be inhibited by resveratrol through a block on
G1-S phase and by an increase in apoptosis. It supports the conjecture that red wine consumption may have a beneficial
effect on cardiovascular mortality. ( J Vasc Surg 2005;42:1190–7.)
Clinical Relevance: Our results suggest that resveratrol inhibits, in a dose-dependent manner, smooth muscle cell
proliferation, which may help to partially explain a beneficial effect of wine drinking. This inhibition is related to an early
block in the cell cycle and also to a dose-dependent apoptotic effect. The present study demonstrates that resveratrol not
only is an indirect marker of a healthy life style and alimentation but may also be directly responsible for the French
paradox.Previous studies have hypothesized that the “French
paradox,” the observation that the French have a lower-
than-expected cardiovascular mortality rate despite a high
intake of saturated fats and a high serum cholesterol
level,1-7 may be the consequence of wine drinking. Mod-
erate red wine consumption has a favorable effect on ath-
erosclerotic disorders, with a lowered incidence of coronary
heart disease and atherosclerosis.8-9 Red wine has been
shown to have a beneficial impact on lipoproteins, platelet
activation, and aggregation.1,10-11 Among components of
red wine, the polyphenols—in particular resveratrol (3,4=,5
trihydoxy-trans-stilbene)—are proposed to be responsible
for the protective effect of red wine in cardiovascular dis-
ease.12-14 Since vascular smooth muscle cell (SMC) migra-
tion from the media to the intima and its subsequent
proliferation is the sine qua non of atherogenesis, the aim of
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MATERIALS AND METHODS
Cell culture. Primary cultures of SMCs were derived
from newborn calf thoracic aorta by the explant method, as
previously described.15 Cells were grown in Dulbecco
modified Eagle’s medium/F12 (Gibco, Carlsbad, Calif)
with 10% penicillin-streptomycin-amphotericin B and 20%
fetal bovine serum (FBS) (Gemini, Calabasas, Calif) at 37°C
and 5% carbon dioxide. Experiments were conducted on
SMCs between passages 6 to 10. Trans-resveratrol (Sigma-
Aldrich Chemical, St. Louis, Mo) was dissolved in dimethyl
sulfoxide (DMSO) at a stock concentration of 104 M and
stored at 20°C.
Cell proliferation study. SMCs were seeded in 6-well
plates overnight and then incubated for 24 hours at 37°C in
either serum-free medium supplemented with 108 M
selenium, 106 M insulin, and 5 g/mL transferin,16 or
medium containing 1% or 10% FBS. In parallel experi-
ments, resveratrol was added to a final concentration of
104, 105 or 106 M. Medium was changed every 48
hours, and a new dose of resveratrol added at the same
time. On days 1 and 3, cells were washed twice with cold
phosphate-buffered saline (PBS), harvested by trypsiniza-
tion, and an aliquot counted with a hemocytometer. The
number of cells was expressed as the percentage increase in
cell number compared with day 0.
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in 6-well plates and incubated with 10% medium for 24
hours at 37°C. Resveratrol (104, 105, or 106 M) was
then added. At each experimental time point, SMCs were
trypsinized, washed twice with PBS, and then progressively
fixed with 70% ethanol overnight at 4°C. Cells were then
centrifuged and incubated with Rnase (1 mg/mL) for 30
minutes at 37°C before staining in the dark with propidium
iodide at a final concentration of 0.05 mg/mL. Cell cycle
analysis was performed by using a Becton Dickson Immu-
nocytometry System (San Jose, Calif) and ModFit software
(Verity Software, BD Biosciences, Mississauga, Ontario,
Canada).
Western blot analysis of proliferating cell nuclear
antigen, cyclin E, cyclin-dependent kinase 2, and BAD
activation. SMCs were seeded in 6-well plates and incu-
bated with 10% medium for 24 hours at 37°C. Resveratrol
(105 M) was then added. After experimentation, SMCs were
washed twice in ice-cold PBS and lysed by scraping in lysis
buffer containing 50 mM HEPES pH 4 (N-2-hydroxyethyl
piperazine-N=-2-ethane-sulfonic acid), 150 mM sodium chlo-
ride, 10% glycerol, 1% Triton X-100, 1.5 mmol/L magne-
sium chloride, 1 mM ethylene glycol-bis (-aminoethyl
ether)-N,N,N=,N=-tetraacetic acid, 100 mM sodium fluoride,
10 mM sodium pyrophosphate, 1 mM sodium orthovana-
date, 10 g/mL leupeptin, 10 g/mL aprotin, and 1 mM
phenylmethylsulfonyl fluoride.
Lysed cells were sonicated and centrifuged for 20 min-
utes at 14,000 g, and the supernatants were collected.
Protein content was determined using the BioRad protein
assay system according to the manufacturer’s protocol (Bio-
Rad Laboratories, Hercules, Calif). Cell lysates containing
30-60 g protein were loaded in each lane and separated in
1% sodium dodecyl sulfate polyacrylamide gels (American
Bioanalytical, Natick, Mass) and then transferred to nitro-
cellulose membrane (Amersham, Arlington, Ill). Mem-
branes were incubated in a 5% bovine serum albumin
TBS-T blocking solution. Proliferating cell nuclear anti-
gen (PCNA), a proliferation-sensitive DNA replication
protein whose synthesis is modulated during the cell
cycle, cyclin-dependent kinase 2 (CDK2), an S-phase cy-
clin dependent kinase, and cyclin E, an S-phase cyclin,
which are both involved in the G1-S cell cycle phase tran-
sition. (Santa Cruz Biotechnology, Santa Cruz, Calif) and
Akt antibodies (Cell Signaling Technology; Beverly, Mass)
were used according to company’s suggested guidelines
with appropriate secondary antibodies.
Band densities on autoradiograms were measured with
a Image Quant densitometer (Molecular Dynamics; Sunny-
vale, Calif) within the linear range of the film. Band densities
were normalized against the control lane (untreated cells).
Terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick-end labeling assay and morphologic
analysis. Apoptosis was evaluated by using an in situ POD
cell death detection kit (Roche Diagnostics GmbH, Mann-
heim, Germany). SMCs maintained in 10% FBS were ex-
posed to different concentrations of resveratrol for 24
hours. Positive control was SMC exposed to 20 uM tumornecrosis factor for 4 hours. SMCs were visualized under a
light microscope at 200 magnification and digitally pho-
tographed (Olympus America, Woodbury, NY). The apo-
ptotic index (AI) was calculated as the number of apoptotic
cells/total number  100.
Statistical analysis. Data are reported as mean stan-
dard error of the mean (SEM). Data for the proliferation
studies were analyzed by taking the mean of three counts
for each well and then considering each of the six indepen-
dent wells as a separate data point. At least three indepen-
dent proliferation experiments were performed for each
study, each of which yielded similar, statistically significant
results. For flow-activated cell sorter analysis, data from at
least three separate and distinct experiments were utilized.
For statistical analysis of the Western blot studies, densito-
metric data from at least three blots obtained from separate
and distinct experiments were assessed after normalization
with the band intensity for the control lane (untreated
cells). Statistical significance was determined by two-way
analysis of variance with a multiple comparison method
using Statview software (SAS Campus Drive, Cary, NC).
Fig 1. Effect of resveratrol on smooth muscle cell (SMC) prolif-
eration. SMCs maintained in 10% fetal bovine serum (FBS) were
exposed to different concentrations of resveratrol for up to 3 days.
A, Results for a typical experiment. The x-axis represents the time
course of the experiment, and the y-axis represents the cell number/
well measured with a hemocytometer. The control is not exposed
to resveratrol. *P  .005 compared with the control. P  .01
compared with resveratrol 106 M. B, This graph shows the mean
SEM for three separate experiments, normalized as a percentage
increase on day 1 and day 3. *P  .001 compared with control.
P  .002 compared with resveratrol 106 M. There is a dose
dependent effect of resveratrol on SMC proliferation.P  .05 was considered significant.
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 6 Poussier et al 1190.e3RESULTS
Resveratrol inhibited SMC proliferation in a dose-
dependent manner. SMC proliferation in the presence of
DMSO was similar to control (Appendix Fig 1 [online
only]). Fig 1 shows that in experiments performed with a
media containing 10% FBS, there was no significant differ-
ence in proliferation of SMCs containing 106 M resvera-
trol compared with the control. However, SMC prolifera-
tion was strongly inhibited in the presence of 104 or 105 M
resveratrol compared with control SMCs or SMCs treated
with 106 M resveratrol. In additional experiments, this
pattern was sustained for up to 7 days (Appendix Fig 2
[online only]). For experiments performed using media
containing only FBS 1%, there was also a similar significant
decrease proliferation in SMCs treated with 104 and
Fig 2. Flow cytometry studies of smooth muscle cell
“Methods” for details. A, Representative flow cytometri
105 M for 24 hours. The y-axis represents the percent
(DNA synthesis, green curve), or G2-M (mitosis, second
different experimental conditions. There is a significant i
treated cells. B, Mean results in percentage of three expe
phase of the cell cycle, respectively G0-G1, S, and G2-M
day 1.P .04 compared with the same phase of control da
with resveratrol 105 M.105 M resveratrol (Appendix Fig 3 [online only]).Resveratrol induced a block between G1 and S phases of
the cell cycle. Fig 2 shows that SMCs treated with 105 M
resveratrol for 1 day had a significant block between G0-G1
and S phases of the cell cycle compared with the control
(P  .001). In cells treated with 105 M resveratrol for 24
hours, the G0-G1 phase represented 89% of the cells, the S
phase, 5%; and the G2-M phase, 6%. In contrast, for control
nontreated cells, each phase was represented respectively at
49%, 33%, and 18%. The same block was found in cells
exposed to resveratrol 104 M (P  .0001 compared with
control) (Appendix Fig 4 [online only]). Cells treated with
resveratrol 106 M, had no significant difference in cell
cycle distribution compared with control.
By day 5, SMC attained confluence and the G0-G1
block persisted for the resveratrol 104 M and 105 M
groups and in the presence of either 1% or 10% FBS
C) exposed to resveratrol 105 M for 24 hours. See
grams of SMC in the presence of absence of resveratrol
f cells which are in the G0-1 (growth, first red curve), S
urve), phase of the cell cycle. The x-axis represents the
se in the percentage of cells in S phase, in the resveratrol
ts. All percentages have been grouped according to the
s. *P .0001 compared with the same phase of control
here is a block between G0-G1 and S phase in the cell cycles (SM
c histo
age o
red c
ncrea
rimen
phase
y 1. T(Appendix Fig 5 [online only]). However, for the resvera-
anges
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in G0-G1 phase.
We attempted to determine the underlying mechanism
of this block. However, Fig 3 shows that treatment of
SMCs with resveratrol does not alter PCNA, CDK2, or
cyclin E levels.
Resveratrol exposure resulted in apoptosis of SMCs.
Fig 4 shows the results of the terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick-end labeling (TUNEL)
assay for SMCs treated with resveratrol for 24 hours. There
was a dose-dependent apoptotic effect upon exposure of
SMCs to resveratrol. The control group had 6.9% apoptotic
cells and SMCs treated with 106 M resveratrol had 6.5%
apoptotic cells. However, cells exposed to 105 M or
104 M resveratrol had 13.3% and 21% apoptotic cells, re-
spectively (P  .005 for both groups). Fig 4 also demon-
strates that there was no significant change in SMC mor-
phology at 24 hours. There was, as expected, a decrease of
SMC proliferation inversely proportional to increasing res-
veratrol concentration. There was no morphologic evi-
dence of any gross damage to the cells, even at 72 hours
(Appendix Fig 6 [online only]).
DISCUSSION
Renaud et al17 first reported a 21% reduction of the
cancer rate among moderate wine drinkers. Since then,
most experimental studies have concentrated on the effects
of polyphenols, especially resveratrol, on the prevention of
carcinogenesis.18 Resveratrol has been widely studied in
tumor cells and is being viewed as a cancer chemopreven-
tive agent, as an antioxidant, and as an antimutagenic.19-22
Resveratrol has been demonstrated to inhibit proliferation
of several cells lines, such as human malignant and nonma-
lignant breast epithelial cells,23 human prostate cancer
cells,24 human HeG2 hepatoblastoma cells25 and human
Fig 3. Western blot for proliferating nuclear antigen (P
smooth muscle cells exposed to resveratrol 105 M for 2
each lane. The time course of experimentation is listed
different experiments for each protein. No significant chcolon tumor cells line SW480.22,26However, there are only a very few studies on the effect
of resveratrol on SMC proliferation.27-29 In an earlier
study, we demonstrated that dealcoholized red wine and its
polyphenol fraction could inhibit SMC proliferation in a
dose-dependent fashion.15 In that study, we presented
preliminary findings that resveratrol at a concentration of
104 M could also inhibit SMC proliferation.
The present studies extend these results. We now dem-
onstrate that resveratrol inhibition of SMC proliferation is a
dose-dependent phenomenon. We also observed that res-
veratrol had a similar effect on proliferation when added to
SMCs in either 1% or 10% FBS medium (Appendix Fig 2
and Fig 5 [online only]). In fact, the observation that the
mitogenic 10% medium cannot attenuate the resveratrol
effect provides an important clue that the mechanism of
resveratrol inhibition is not related to regulation of secre-
tion of growth factors but may be due to an intrinsic cellular
effect of resveratrol.
The findings of this study also suggest that resveratrol
inhibition of SMC proliferation may be occurring through
two different paths. The first path is through an arrest of cell
cycle proliferation at G1 and the second path is through
enhancing apoptosis. Previous investigations have observed
an impact of resveratrol on the cell cycle of different cell
types. Although the reports uniformly suggest an arrest of
the cell cycle progression before the M phase, the precise
location of the block is not clear, either a G1-S or S-G2
phase block depending on the cell type studied.30-35 For
example, in SMCs, Zou et al13 found a G1-S block in the
cell cycle progression; however, the dose they used was 5 to
10 times higher than what we used.
The effect of resveratrol on cell cycle regulators has
been studied in several different cell types but not in SMCs.
However, to underscore the complexity of the studies,
reports in the literature have produced conflicting results.
), cyclin-dependent kinase 2 (CDK2), and cyclin E of
urs. Total Akt is used to assure equal protein loading of
each blot. These blots are representative of at least 3
were observed.CNA
4 ho
belowFor instance, resveratrol has been reported to increase the
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(Kip1) when added to different cancer cell lines.32,36-37
Resveratrol decreases the phosphorylation of retinoblas-
toma protein, a repressor of progression towards S phase,
on human lymphocytes and human epidermoid carcinoma
cells31,38 and decreases the level of cyclin A, B, D, and E,
and CDK 2, 4, and 6 in human lymphocytes, human
epidermoid carcinoma cells, prostate cancer cells, and
breast cancer cells.32,37,39 In colon cancer cells, an in-
creased level of cyclin A and E have been observed.
In one study on SMCs, resveratrol caused a dose-
dependent increase in intracellular p53, a protein that
senses DNA damage and can halt progression of the cell
cycle in G1, and p21 (WAF1/CIP1).
27 In another study,
however, it decreased cellular levels of the cyclin-dependent
kinase inhibitors p21 (WAF1/CIP1) and p27 (Kip1).9
We also explored key steps of cell-cycle regulation.
However, we found resveratrol had no significant affect on
Fig 4. Effect of resveratrol on smooth muscle cell (SM
fetal bovine serum (FBS) were exposed to different co
TUNEL images of SMCs exposed to varying concentra
exposed to 20 uM tumor necrosis factor. The darken
original magnification). B, The five bars represent t
groups, respectively. Error bars reflect the SEM. *P
compared with resveratrol 106 M group, Kruskal-Wa
different than negative control.PCNA, a proliferation-sensitive DNA replication proteinwhose synthesis is modulated during the cell cycle; CDK2,
an S-phase cyclin dependent kinase, and cyclin E, an
S-phase cyclin, which are both involved in the G1-S cell
cycle phase transition (Appendix Fig 7 [online only]).
One of the important findings of our study was a
significant increase in apoptosis in SMC exposed to 105 or
104 M resveratrol by the TUNEL assay. This result con-
firms previous reports on an increase in apoptosis with
resveratrol treatment in different cell types.18,40 However,
Zou et al,13 using a flow cytometry technique in SMCs
exposed to resveratrol, could only detect2% of apoptotic
cells. The reasons for this discrepancy are unclear but could
be due to the different dose of resveratrol they used.
The relevance of the concentration of resveratrol used
in this study is an important consideration. In many animal
studies, the dose of resveratrol chosen is at least 1 mg/kg.
For a 70-kg person, this corresponds to a daily intake of 14
liters of red wine (the average concentration of resveratrol
apoptosis by TUNEL assay. SMCs maintained in 10%
trations of resveratrol for 24 hours. A, Representative
of resveratrol for 24 hours. Positive control was SMCs
uclei indicate positive staining (Magnification 200
ean percentage of apoptotic cells in each treatment
compared with resveratrol 106 M group. **P .001
st. Resveratrol 106 M treatment was not significantlyC)
ncen
tions
ed n
he m
.005
llis tebeing 5 mg/L). However, if one considers a more reason-
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70-kg person, this translates into a daily resveratrol con-
sumption of 17.8 g/kg. Thus, many of the in vivo and in
vitro studies in the literature may be irrelevant since they use
resveratrol at a concentration from 1 to 360 mg/kg.8,41-46
Another important aspect to consider is the bioavail-
ability of polyphenols. The concentration of polyphenols
(phenolic acids and flavonoids) in red wine is 0.1 to 15
mg/L.1 They are rapidly absorbed into the blood stream,
approximately 30 minutes after ingestion. The three most
important polyphenols are resveratrol (228.25 g/mol),
quercetin (338.26 g/mol), and catechin (287.25 g/mol).
Andlauer instilled in rat small bowel a solution containing
physiologic, nutritionally relevant concentrations of res-
veratrol (57  106 M) and measured a total plasma
concentration of 1.17  106 M, similar to the lowest
concentration used in our study. The lowest dose for which
we got a significant difference in cell proliferation was 105 M,
lower than those found by Zou et al,28 who only found
significant difference with 5  105 and 104 M.
We did not observe any difference in cell proliferation
between 106 M resveratrol and the control group. Nev-
ertheless, it does not imply that resveratrol does not have
any effect at this low concentration, because this dose must
be compared with an isolated intake of red wine. The
expected benefits with red wine are probably not the result
of isolated or rare intake of red wine but more from
long-term exposure, as suggested in clinical studies.1 Thus,
although we did not observe an effect of resveratrol on
SMC proliferation at a very low concentration (106 M),
even after 7 days (data not shown), we cannot exclude the
possibility that there would be an effect after a more pro-
longed exposure.
The effects of resveratrol on blood vessels in vivo re-
mains to be fully elucidated. Resveratrol appears to be safe.
It is not cytotoxic with an intraperitoneal injection of up to
1 to 5 mg/kg.47 A high oral intake of resveratrol at a daily
dose of 20 mg/kg in rats (nearly 1,000 times a regular
intake consumed by a 70-kg person) was not observed to
have any harmful effects.47 There were no adverse effects
on the variables tested (body weight, food and water con-
sumption, hematology and clinical chemistry, gross nec-
ropsy, and histopathology), indicating that trans-resveratrol
had a large safety margin. These in vivo data are consistent
with the previous in vitro studies. In our earlier report, we
found no evidence of SMC damage using a colorimetric lactic
dehydrogenase assay.15 This was confirmed by another study
on lymphocytes that used a 1-methyltetrazole-5-thiol (MTT)
assay conversion of tetrazolium compound to a formazan
product.34 Lastly, in the present study, our morphologic
observation did not demonstrate any significant changes.
CONCLUSION
Our results suggest that resveratrol inhibits SMC pro-
liferation in a dose-dependent manner, which may help to
partially explain a beneficial effect of wine drinking. Thisinhibition is related to an early block in the cell cycle,
between G0-G1 and S phases, and also to a dose-dependent
apoptotic effect. Although the etiology of cardiovascular
morbidity involves numerous variables, this speculation is
worthy of further testing. According to a report from the
American College of Cardiology, moderate drinkers “have
a 40 percent to 50 percent reduction in coronary artery
disease compared with individuals who are abstinent” In
1996, the American Heart Association reported that “the
lowest mortality occurs in those who consume one or two
drinks per day.”48
The mechanism underlying the putative cardioprotec-
tive effects are not well defined, however. The benefits of
resveratrol on atherosclerosis may not only be limited to an
antiproliferative effect but may also include other actions.1
Resveratrol, for instance, is an agonist for the estrogen recep-
tor because of its similarity to diethylstilbestrol, a synthetic
estrogen.49 Estrogen has been shown to have a beneficial
effect on atherogenesis and on intimal hyperplasia.50 Resvera-
trol also inhibits platelet aggregation, increases high-density
lipoprotein, and decreases low-density lipoprotein oxida-
tion.1 It has been shown to increase cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophos-
phate (cGMP) phosphodiesterases, raising the platelet lev-
els of cAMP and cGMP, and causing a decrease in the levels
of platelet cytosolic calcium and lower activity levels of
platelets.51 Resveratrol is more powerful as an antioxidant
for low-density lipoprotein than vitamin E.11,52 All these
beneficial factors and probably many others may be respon-
sible for the observed beneficial effects of resveratrol and
red wine. In vivo studies remain to be done in order to
assess its physiologic properties and its involvement in the
low morbidity observed among Mediterranean countries,
particularly France.
Future studies will also need to be performed to address
the bioavailability of resveratrol for SMCs, the contribution
of alcohol to the resveratrol effect, and direct clinical evi-
dence of resveratrol effect on atherosclerosis. The present
study demonstrates that resveratrol is not only an indirect
marker of a healthy life style and alimentation but may also
be directly responsible for the French paradox.
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Volume 42, Number 6 Poussier et al 1190.e9Appendix Fig 1. Absence of effect of dimethyl sulfoxide (DMSO) compared with resveratrol (105 M) and control on
smooth muscle cell (SMC) proliferation. SMC maintained in 10% fetal bovine serum were exposed to DMSO (104 M)
or resveratrol (105 M) for up to 3 days. The x-axis represents the time course of the experiment, and y-axis represents
the cell number/well measured with a hemocytometer. The control is not exposed to resveratrol or DMSO. *P .005
compared with the control. There is no effect of DMSO on SMC proliferation.
Appendix Fig 2. Effect of resveratrol on smooth muscle cell (SMC) proliferation. SMC maintained in 10% fetal bovine
serum were exposed to different concentrations of resveratrol for up to 7 days. Result of a typical experiment. The x-axis
represents the time course of the experiment, and y-axis represents the cell number/well measured with a hemocy-
tometer. The control is not exposed to resveratrol. *P  .005 compared with the control. P  .01 compared with
resveratrol 106 M.
JOURNAL OF VASCULAR SURGERY
December 20051190.e10 Poussier et alAppendix Fig 3. Effect of resveratrol on smooth muscle cell (SMC) proliferation in 1% fetal bovine serum (FBS).
SMCs maintained in 1% FBS were exposed to different concentrations of resveratrol for up to 3 days. A, Results for a
typical experiment. The x-axis represents the time course of the experiment and y-axis represents the cell number/well
measured with a hemocytometer. The control is not exposed to resveratrol. *P  .005 compared with the control.
P  .01 compared with resveratrol 106 M. B, This graph shows the mean  SEM for three separate experiments,
normalized as a percentage increase on day 1 and day 3. *P .001 compared with control. There is a dose-dependent
effect of resveratrol on SMC proliferation, even with minimal amounts of serum.
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 6 Poussier et al 1190.e11Appendix Fig 4. Representative flow cytometric histograms of smooth muscle cells (SMC) in absence of resveratrol
(control) or in the presence of 106, 105, or 104 M resveratrol (right) for 24 hours. The y-axis represents the
percentage of cells which are in the G0-1 (growth, first red curve), S (DNA synthesis, green curve), or G2-M (mitosis,
second red curve), phase of the cell cycle. The table depicts the percentages according to the phase of the cell cycle. After
24 hours, there is a block between G0-G1 and S phase in the cell cycle with resveratrol 105 and 104 M. By day 5,
SMCs attained confluence and the G0-G1 block persisted for the resveratrol 104 M and 105 M group. However, for the
resveratrol 106 M and control groups, up to 90% of the cells were in G0-G1 phase.
JOURNAL OF VASCULAR SURGERY
December 20051190.e12 Poussier et alAppendix Fig 5. Flow cytometry studies of smooth muscle cells (SMC) maintained in 1% or 10% fetal bovine serum
(FBS) and exposed to resveratrol 105 M for up to 5 days. Representative flow cytometric histograms of SMC are
shown and the table depicts the percentages according to the phase of the cell cycle. The y-axis represents the
percentage of cells which are in the G0-1 (growth, first red curve), S (DNA synthesis, green curve), or G2-M (mitosis,
second red curve), phase of the cell cycle. The x-axis represents the different experimental conditions. The profile of
resveratrol 105 M is the same in SMC maintained with either 1% or 10% FBS.
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 6 Poussier et al 1190.e13Appendix Fig 6. Effect of resveratrol on smooth muscle cell (SMC) morphology. SMCs maintained in 10% fetal
bovine serum (FBS) were exposed to different concentrations of resveratrol 106 to 104 M for up to 3 days.
Representative light microscopic images are shown (40 original magnification). There was no morphologic evidence
of any gross damage to the cells, even at 72 hours, at any concentration.
JOURNAL OF VASCULAR SURGERY
December 20051190.e14 Poussier et alResveratrol                             P53 & CDK Inhibitor WAP/Cip (p21Cip1/WAF1, p27Kip1,  
                  
     p16Ink4a, p15Ink4b, p18Ink4, p19Ink4d   
Cyclin D1/CDK4 or Cyclin D3/CDK6
        Cyclin E/CDK2 
          phosphorylation 
                pRb (retinoblastoma protein) 
      release E2/F & DP1 
      expression cyclin E, cyclin A, CDK2  
      cyclin E/CDK2 
           
G1 S (DNA replication) 
cyclin A/CDK2
                                         TGF cyclin A/CDK1
       cyclin B/CDK1                     G2
           M     
PCNA 
p57Kip2) 
Appendix Fig 7. Schematic of cell cycle control by cyclins. The cell cycle is regulated by different protein. Proliferating
nuclear antigen (PCNA) is an universal activator of the cell cycle for many cells. The cell cycle is also regulated between
each phase by different protein, the cyclin and cyclin-dependent kinase (CDK). They work together as a complex and
are different at each step of the cell cycle. In the current report, we studied the cyclin E/CDK2 complex. Acting after
the complexes cyclin D1/CDK4 and cyclin D3/CDK6, the complex cyclin E/CDK2 is regulating the transition
between G0-G1 phase and S phase.
